<DOC>
	<DOCNO>NCT02957656</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity one dose H7N9 pandemic live attenuate influenza vaccine ( H7N9 pLAIV ) follow AS03-adjuvanted H7N9 pandemic inactivate influenza vaccine ( H7N9 pIIV ) .</brief_summary>
	<brief_title>Safety Immunogenicity Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant</brief_title>
	<detailed_description>This study evaluate safety immunogenicity one dose H7N9 pandemic live attenuate influenza vaccine ( H7N9 pLAIV ) follow AS03-adjuvanted H7N9 pandemic inactivate influenza vaccine ( H7N9 pIIV ) . This study enroll healthy adult choose study group join . Participants Group 1 receive one dose H7N9 pLAIV inpatient set study entry ( Day 0 ) . They remain isolation unit least Day 9 . They also receive one dose AS03-adjuvanted H7N9 pIIV Day 84 . Participants Group 2 receive one dose AS03-adjuvanted H7N9 pIIV study entry ( Day 0 ) second dose AS03-adjuvanted H7N9 pIIV Day 84 . Participants Group 3 receive one dose AS03-adjuvanted H7N9 pIIV study entry ( Day 0 ) . All participant attend multiple study visit Day 264 . Study visit may include blood collection , physical examination , nasal wash nasal wick procedure . These three group compare two historical control group receive one dose H7N9 pLAIV study entry ( Day 0 ) , one dose H7N9 pLAIV Day 28 , one dose unadjuvanted H7N9 pIIV Day 84 .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Influenza Birds</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Adult male nonpregnant , nonbreastfeeding female 20 year 49 year age , inclusive . Children recruit enrol study apparent risk group , safety consideration , need isolation . Are good health , determine medical history target physical examination ensure exist medical diagnosis condition ( except exclusionary ) stable . More information criterion find protocol . Agree storage blood specimens future research . Available duration trial . Subjects must willing able remain within Isolation Unit specify duration confinement . Provide write informed consent prior initiation study procedure , include future use specimen . Female subject childbearing potential must agree use effective birth control method duration study ( example , pharmacologic contraceptive include oral , parenteral , transcutaneous delivery ; condom spermicide ; diaphragm spermicide ; intrauterine device ; abstinence heterosexual intercourse , surgical sterilization ) . All female subject consider childbearing potential except undergone hysterectomy tubal ligation menopause occur least 1 year prior study . Agrees participate another clinical trial investigational product entire duration study . Oral temperature less 100.4°F . Pulse 50 115 bpm , inclusive . Systolic blood pressure 85 150 mm Hg , inclusive . Diastolic blood pressure 55 95 mm Hg , inclusive . Female subject childbearing potential must negative urine serum pregnancy test within 24 hour prior study vaccination . Pregnancy determine positive human choriogonadotropin ( betaHCG ) test . Currently breastfeed plan breastfeed point duration study . Evidence clinically significant neurologic , cardiac , pulmonary , hepatic , rheumatologic , autoimmune , renal disease history , physical examination , electrocardiogram ( EKG ) and/or laboratory study include urine testing . Alanine aminotransferase ( ALT ) level great 2 time upper normal limit exclusionary baseline , prior vaccination . Any current illness require daily medication follow : vitamin , birth control , antihypertensive medication , antihistamine , antidepressant medication , cholesterollowering medication , treatment gastroesophageal reflux disease , thyroid medication unless approve PI . Behavioral cognitive impairment psychiatric disease opinion investigator affect ability subject understand cooperate study protocol . Previous enrollment H7 H9 influenza vaccine trial study avian influenza vaccine . Seropositive H7N9 influenza A virus ( serum HAI titer great 1:8 ) . Positive urine drug toxicology test indicate narcotic use/dependency . Have medical , occupational , family problem result alcohol illicit drug use past 12 month . Other condition opinion investigator would jeopardize safety right subject participate trial would render subject unable comply protocol . Have history severe reaction follow previous immunization license unlicensed influenza virus vaccine . Have know hypersensitivity allergy egg , egg chicken protein , squalenebased adjuvant , component study vaccine . Allergy oseltamivir determine subject report . Current diagnosis asthma reactive airway disease ( within past 2 year ) . History GuillainBarré Syndrome . Positive enzymelinked immunosorbent assay ( ELISA ) confirmatory Western blot test human immunodeficiency virus1 ( HIV1 ) . Positive ELISA confirmatory test ( e.g. , recombinant immunoblot assay ) hepatitis C virus ( HCV ) . Positive hepatitis B virus surface antigen ( HBsAg ) ELISA . Known immunodeficiency syndrome . Use corticosteroid ( exclude topical preparation ) immunosuppressive drug within 30 day prior vaccination . Receipt live vaccine within 4 week kill vaccine within 2 week prior study vaccination . Planned receipt vaccine first study vaccination followup visit approximately 180 day final study vaccination . History asplenia . Use anticancer chemotherapy radiation therapy ( cytotoxic ) within 36 month prior vaccination . Have know active neoplastic disease history hematologic malignancy . Receipt blood bloodderived product ( include immunoglobulin ) within 6 month prior study vaccination . Current smoker unwilling stop smoking duration inpatient stay . A current smoker include anyone state currently smoke use amount tobacco product , include electronic cigarette . After admission unit , nicotine patch provide current smoker request inpatient portion study . Travel Southern Hemisphere within 14 day prior study vaccination . Travel cruise ship within 14 day prior study vaccination . Receipt another investigational vaccine drug within 30 day prior study vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>